Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors

NCT05585034 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma
Melanoma Excluding Uveal Melanoma
Non-small Cell Lung Cancer, Squamous or Non-squamous
Urothelial Carcinoma
Renal Cell Carcinoma, Clear Cell
Castration-resistant Prostate Cancer
Ovarian Cancer, Epithelial
TNBC - Triple-Negative Breast Cancer
Colorectal Cancer

Interventions

BIOLOGICAL: XmAb®808
BIOLOGICAL: Keytruda® (pembrolizumab)

Sponsor

Xencor, Inc.